2015/07/02 – Quantum Genomics speeds its development work in the field of heart failure

Quantum Genomics (Alternext – FR0011648971 – ALQGC), ), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces its intention to speed its research and development work on its QGC101 drug candidate for the prevention and treatment of heart failure. The promising results obtained in trials in dogs by a major company in the field of animal health, support Quantum Genomics’ ambitions in this indication.

[button link=”http://www.quantum-genomics.com/www/wp-content/uploads/2015/07/QGC_CP_INSERM-OTTAWA_02072015_VF-EN.pdf” target=”_blank” title=”Download Press Release” size=”small” color=”red”]